Asia Pacific Diabetes Care Devices Market Size & Share 2025 - 2034

Asia Pacific Diabetes Care Devices Market Size

The Asia Pacific diabetes care devices market was valued at USD 12.2 billion in 2024 and is projected to grow from USD 13.5 billion in 2025 to USD 39 billion by 2034, expanding at a CAGR of 12.5%, according to the latest report published by Global Market Insights Inc. This consistent growth is driven by several factors such as increasing incidence of diabetes, increasing technological upgradations in diabetes care devices, and public and private investment increases for diabetes care.

Diabetes care devices are a number of medical devices to assist patients with diabetes in managing the condition to their best potential. The devices are a key in monitoring blood sugar levels, insulin administration, and general management of diabetes. Major companies in the industry include F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care, Novo Nordisk, and Medtronic.
 

The market increased from USD 9 billion in 2021 to USD 11 billion in 2023, largely due to the increased adoption of digital technologies, shift in consumer behaviour preferring more advanced and sustainable solutions, and the growing demand in emerging markets. Moreover, companies also capitalized on post pandemic momentum, expanding their product portfolio, and optimizing supply chain to meet the changing expectations. Thus, all these factors collectively contributed to the upward growth of the market during the period.
 

The growth of the Asia Pacific diabetes care devices market is strongly driven by the rising prevalence of diabetes across the region. In the WHO South-East Asia Region, nearly 246 million people aged 30 years and above are estimated to have diabetes. Alarmingly, more than half of these individuals are unaware of their condition. Of those diagnosed, only 68 million are currently receiving treatment, highlighting a significant treatment gap of 177 million. Diabetes is responsible for approximately 480,000 deaths annually in this region, underscoring the urgent need for effective management and care solutions. Moreover, population ageing in Asia Pacific is occurring at an unprecedented pace, driven by rapid declines in fertility and mortality rates, alongside rising life expectancy.
 

In several Asia Pacific countries, the transition from 7% to 14% of the population aged 65 and above is taking place within 20 to 25 years a stark contrast to the 50+ years it took in most European nations. This accelerated ageing process is contributing to a higher prevalence of chronic conditions such as diabetes, particularly among older adults who require frequent monitoring and care. As the ageing population grows, so does the demand for reliable and user-friendly diabetes care devices, making this segment a key driver of market expansion across the Asia Pacific region.
 

Additionally, growing government initiatives across the Asia Pacific region are playing a pivotal role in addressing the rising prevalence of diabetes and accelerating the market growth. For instance, the Colombo Call to Action, adopted by countries in the WHO South-East Asia Region, outlines a unified commitment to strengthen diabetes prevention and control.
 

Diabetes care devices refer to a range of medical devices designed to help individuals with diabetes manage their condition effectively. These devices play a crucial role in monitoring blood glucose levels, administering insulin, and overall diabetes management.
 

Asia Pacific Diabetes Care Devices Market Trends

• Technological innovation is a key driver propelling the growth of the market. Companies across the region are actively investing in the development of cost-effective, user-friendly, and minimally invasive devices that offer accurate and real-time monitoring for diabetic patients. These advancements are particularly crucial in Asia Pacific, where the demand for personalized and accessible healthcare solutions is rising rapidly.
   
• For instance, Sibionics, a regional player, received CE Mark approval for its GS1 continuous glucose monitoring system, which offers real-time glucose tracking and is designed for affordability and ease of use. Similarly, Ypsomed introduced smartphone-enabled bolus delivery via its mylife YpsoPump, enhancing convenience for insulin users.
   
• Major companies such as Medtronic and Abbott continue to expand their footprint in Asia Pacific through localized innovations, strategic partnerships, and regulatory collaborations. These efforts are aimed at improving device accessibility and tailoring solutions to regional healthcare needs.
   
• Additionally, self-monitoring blood glucose (SMBG) devices, which was valued at USD 19.8 billion in 2024 and is expected to reach USD 58.9 billion in 2034, growing at a CAGR of 11.8% from 2025 to 2034, have evolved significantly, with more compact and ergonomic designs that enhance portability and comfort. The integration of AI and data analytics into diabetes care devices is also gaining traction, enabling smarter and more personalized disease management.
   
• As these technologies become more widely available and supported by government initiatives and digital health infrastructure, their adoption is accelerating across both urban and rural areas of the region further fueling market growth.
   

Asia Pacific Diabetes Care Devices Market Analysis

Based on the product, the market is segmented into devices and consumables. The devices segment is further segregated into blood glucose monitoring devices and insulin delivery devices. The blood glucose monitoring devices segment is further bifurcated into self-monitoring blood glucose meters, continuous glucose monitors. This segment was valued at USD 4.1 billion in 2024 and is projected to reach USD 16.1 billion by 2034, growing at a fastest CAGR of 14.8%. In comparison, the insulin delivery devices segment, valued at USD 4 billion in 2024, is expected to grow to USD 11 billion by 2034.
 

• Blood glucose monitoring devices such as continuous glucose monitors (CGMs) and self-monitoring blood glucose (SMBG) meters are critical devices for diabetes management throughout the Asia Pacific region. They enable patients to make informed choices about diet, exercise, and insulin therapy, thus enhancing glycemic control and minimizing the risk of complications.
   
• Ongoing monitoring is especially important in averting acute states such as hyperglycemia and hypoglycemia. Real-time monitoring capability improves patient compliance and facilitates timely clinical intervention, in line with the region's increasing focus on digital health integration.
   
• The increasing incidence of diabetes in both emerging and developed Asia Pacific economies is a major growth driver for this segment.
   
• For example, China had a prevalence of diabetes in adults of 11.9% in 2024, says the International Diabetes Federation (IDF).
   
• Likewise, in India, the prevalence of people suffering from diabetes increased from 32 million in 2000 to 101 million in 2024, according to data released in the Journal of the Association of Physicians of India.
   
• These figures highlight the critical imperative for technologically advanced, scalable blood glucose monitoring solutions in accordance with the region's healthcare needs. The rising disease prevalence, along with growing health consciousness and healthcare infrastructure development, is likely to fuel strong market growth in Asia Pacific.

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the Asia Pacific diabetes care devices market is segmented into hospitals, ambulatory surgical centers, diagnostic centers, homecare, and other end users. The home care segment accounted for the market share of 43.9% in 2024.
 

• The growing preference for home-based diabetes management across the Asia Pacific region is significantly driving the adoption of home-use diabetes care devices. These solutions enable individuals to monitor blood glucose levels, administer insulin, and manage their condition independently, reducing reliance on frequent clinical visits and easing pressure on healthcare infrastructure.
   
• Devices such as continuous glucose monitoring (CGM) systems offer real-time insights into glucose fluctuations throughout the day. This empowers users to make informed decisions regarding diet, physical activity, and insulin dosing, enhancing glycemic control and improving overall quality of life.
   
• CGM systems are gaining traction among diabetes patients in Asia Pacific, particularly in urban centers where digital health adoption is accelerating. Additionally, home-based care facilitates personalized treatment plans, allowing patients to collaborate with healthcare providers to tailor insulin regimens based on lifestyle factors such as meal timing and physical activity.
   
• Also, the geriatric population which is more susceptible to diabetes is increasingly opting for home management to maintain autonomy and reduce hospital visits. Individuals aged 65 and above in countries such as Japan, South Korea, and China are driving demand for convenient, user-friendly homecare solutions. This demographic shift is a key contributor to the expansion of the home-use segment.

China dominated the Asia Pacific diabetes care devices market, with the highest market share of 23.4% in 2024.
 

• This leadership position is driven by the country’s exceptionally high diabetes burden, rapid healthcare infrastructure development, and increasing adoption of advanced medical technologies.
   
• According to the International Diabetes Federation (IDF), China had over 147.9 million adults living with diabetes in 2024, representing more than 12% of its population and nearly 22% of global diabetes cases. This staggering prevalence underscores the urgent need for scalable and effective diabetes management solutions.
   
• The Chinese government has prioritized healthcare modernization, investing heavily in the expansion of hospitals, diagnostic centers, and digital health platforms. These initiatives are fueling demand for innovative diabetes care devices such as continuous glucose monitors (CGMs), insulin pumps, and smart glucometers, which are increasingly being adopted in both clinical and homecare settings to support real-time monitoring and personalized treatment plans.
   
• In parallel, lifestyle changes driven by rapid urbanization and economic growth such as increased consumption of ultra-processed foods and reduced physical activity have significantly contributed to the rising prevalence of type 2 diabetes.
   
• Additionally, the high incidence of comorbidities such as hypertension and dyslipidemia among diabetic patients adds complexity to disease management, further reinforcing the need for comprehensive and technologically advanced care solutions, as reported in The Lancet in 2024.
   

Japan diabetes care devices market is poised to witness lucrative growth between 2025 - 2034.
 

• Japan represents a mature and strategically important market within the Asia Pacific diabetes care devices landscape, largely driven by its rapidly aging population and high prevalence of chronic diseases such as diabetes.
   
• As of recent estimates, Japan has approximately 36.25 million individuals aged 65 and above, accounting for nearly one-third of the country’s total population. This demographic shift is significantly influencing healthcare demand, as older adults are more susceptible to chronic conditions that require continuous monitoring and management.
   
• Diabetes is particularly prevalent among Japan’s elderly population, necessitating frequent blood glucose monitoring and personalized care. This has led to increased adoption of medical devices such as self-monitoring blood glucose (SMBG) meters, continuous glucose monitors (CGMs), testing strips, and lancets. These tools support effective disease management, reduce hospital dependency, and enable elderly patients to maintain independence through home-based care.
   
• Japan’s well-established healthcare infrastructure, combined with strong government support for digital health and aging-in-place initiatives, further accelerates the uptake of advanced diabetes care technologies. As a result, the country continues to play a pivotal role in shaping innovation and growth within the Asia Pacific diabetes care devices market.
   

India diabetes care devices market is poised to witness lucrative growth between 2025 - 2034.
 

• India is emerging as one of the most critical markets for diabetes care devices in the Asia Pacific region, driven by a rapidly growing diabetic population, increasing health awareness, and expanding access to healthcare technologies.
   
• According to the International Diabetes Federation (IDF), India had approximately 89.8 million adults living with diabetes in 2024, reflecting a 10.5% prevalence rate among the adult population.
   
• Additionally, the World Health Organization (WHO) reported, an estimated 77 million adults in India are living with type 2 diabetes, while an additional 25 million are classified as prediabetic, placing them at high risk of developing the condition in the near future. Alarmingly, more than 50% of individuals with diabetes remain undiagnosed, which significantly increases the likelihood of complications if not detected and managed early.
   
• Further, India accounts for one-fourth of the global diabetes population, as published by The Hindu in 2024, underscoring the scale and urgency of the challenge. This growing disease burden is driving demand for effective and accessible diabetes care solutions, particularly self-monitoring blood glucose (SMBG) devices, continuous glucose monitors (CGMs), testing strips, and lancets.
   
• The market is further supported by rising health awareness, government-led screening initiatives, and the expansion of digital health platforms that enable remote monitoring and personalized care. As healthcare infrastructure continues to evolve across both urban and rural areas, India is expected to play a pivotal role in shaping the future of diabetes care in the Asia Pacific region.
   

Australia diabetes care devices market is poised to witness lucrative growth between 2025 - 2034.
 

• Australia is a steadily growing market within the Asia Pacific diabetes care devices landscape, supported by a rising prevalence of diabetes, increasing health awareness, and a strong healthcare system.
• According to the International Diabetes Federation (IDF), Australia had approximately 1.69 million adults living with diabetes in 2024, representing a 7.4% prevalence rate among the adult population. This marks a significant increase from earlier years between 2000 and 2021, the number of people living with diabetes in Australia grew nearly 2.8-fold, from 460,000 to 1.3 million, as reported by the Australian Institute of Health and Welfare.
   
• This upward trend reflects both lifestyle changes and improved diagnostic capabilities but also highlights the growing need for effective diabetes management tools. The market is witnessing increased adoption of self-monitoring blood glucose (SMBG) devices, continuous glucose monitors (CGMs), testing strips, and lancets, which are essential for early detection, ongoing monitoring, and personalized care.
• Australia’s well-established healthcare infrastructure, combined with a proactive approach to chronic disease management, positions the country as a promising market for advanced diabetes care technologies. Continued investment in digital health platforms and home-based care solutions is expected to further accelerate market growth.
   

Asia Pacific Diabetes Care Devices Market Share

• The top 5 players in the Asia Pacific diabetes care devices market F. Hoffmann-La Roche, Abbott Laboratories, Ascensia Diabetes Care, Novo Nordisk, and Medtronic collectively hold a 48% market share. These companies maintain leadership through diversified product portfolios, strategic partnerships, regulatory approvals, and continuous innovation tailored to regional needs.
   
• Abbott Laboratories leads the Asia Pacific market with its widely adopted FreeStyle Libre CGM system and strong manufacturing presence in Singapore. The company has reinforced its position through strategic acquisitions, including the September 2023 acquisition of Bigfoot Biomedical, enhancing its insulin management capabilities and expanding its diabetes care ecosystem.
   
• F. Hoffmann-La Roche continues to be a key player in Asia Pacific, especially in diagnostics and SMBG devices. Its collaboration with Astellas Pharma Japan to enhance the Accu-Chek Guide Me system and integrate BlueStar, a digital diabetes management tool, reflects its commitment to innovation and regional adaptation.
   
• Overall, the market is witnessing intensified competition and greater diversity, as both established and emerging players continue to evolve their offerings and strategies.
   

Asia Pacific Diabetes Care Devices Market Companies

Few of the prominent players operating in the Asia Pacific diabetes care devices industry include:

• Abbott Laboratories
• ARKRAY
• Ascensia Diabetes Care
• B. Braun Melsungen
• Becton, Dickinson and Company
• Bionime
• Dr. Reddy’s Laboratories
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Insulet
• Medtronic
• Nova Biomedical
• Novo Nordisk
• Platinum Equity Advisors
• Sanofi
• Sinocare
   
• Abbott Laboratories

Abbott Laboratories leads the Asia Pacific diabetes care devices market with its FreeStyle Libre CGM system and strong manufacturing base. Its innovation in sensor technology and strategic acquisitions, such as Bigfoot Biomedical, enhances its regional footprint and product depth.
 

• Ascensia Diabetes Care

Ascensia Diabetes Care holds a solid position in Asia Pacific through its CONTOUR blood glucose monitoring systems, known for accuracy and ease of use. The company is expanding into CGM and digital health, supporting personalized diabetes management across diverse populations.
 

• B. Braun Melsungen

B. Braun Melsungen operates one of its largest Asia Pacific manufacturing hubs in Malaysia, supporting its diabetes care portfolio alongside infusion therapy solutions. Its broad healthcare product base and regional infrastructure strengthen its presence in institutional care.
 

Asia Pacific Diabetes Care Devices Industry News:

• In March 2023, Astellas Pharma Inc. disclosed its partnership with Roche Diabetes Care Japan Co., Ltd. to collaboratively develop and commercialize the Accu-Chek Guide Me blood glucose monitoring system with enhanced accuracy. Additionally, the agreement involved integrating BlueStar, FDA-cleared digital health solution for diabetes patients developed by Welldoc, Inc. and presently accessible in the U.S. and Canada. The primary objective of this collaboration was to enhance the accuracy of the product and attain a competitive edge in the market.
   

The Asia Pacific diabetes care devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Device
  • Blood glucose monitoring devices
    • Self-monitoring blood glucose meters
    • Continuous glucose monitors
  • Insulin delivery devices
    • Insulin pumps
      • Tubed pumps
      • Tubeless pumps
    • Pens
      • Reusable
      • Disposable
    • Other insulin delivery devices
• Consumables
  • Testing strips
  • Lancets
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pumps consumables

Market, By End Use

• Hospital
• Ambulatory surgical centers        
• Diagnostic centers
• Homecare
• Other end use

The above information is provided for the following countries:

• Japan
• China
• India
• Australia
• South Korea
• Taiwan
• Indonesia
• Vietnam